RTTNews | Aug 24, 2021 08:44AM EDT

08:44 Tuesday, August 24, 2021 (RTTNews.com) - Incyte (INCY) said Health Canada has approved with conditions Minjuvi, or tafasitamab, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The approval of Minjuvi is the first marketing authorization for the company in Canada.

Incyte and MorphoSys share global development rights to tafasitamab. Incyte has exclusive commercialization rights to tafasitamab outside the U.S. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S. and is marketed by Incyte under the brand name Minjuvi in Canada.

Read the original article on RTTNews ( https://www.rttnews.com/3220735/incyte-reports-conditional-approval-of-minjuvi-in-canada-for-patients-with-dlbcl.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved